MedTrace Logo

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

NCT04645524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-09-02

No results posted yet for this study

Summary

This is a randomized, 3-period, placebo-controlled, crossover study to examine the efficacy and safety of AD182 and AD504 versus placebo in patients with obstructive sleep apnea.

Conditions

Interventions

DRUG

AD182

Oral capsule administered before bed

DRUG

AD504

Oral capsule administered before bed

DRUG

Placebo

Oral capsule administered before bed

DIAGNOSTIC_TEST

Polysomnography

for all arms

Sponsors & Collaborators

  • Apnimed

    lead INDUSTRY

Principal Investigators

  • Bruce Corser, MD · Intrepid Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-09-01
Completion
2021-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645524 on ClinicalTrials.gov